Chronic statin therapy and the risk of colorectal cancer. Yang, Y., Hennessy, S., Propert, K., Hwang, W., Sarkar, M., & Lewis, J. D. Pharmacoepidemiology and Drug Safety, 17(9):869--876, September, 2008. doi abstract bibtex BACKGROUND AND AIMS: Epidemiologic studies on a potential chemopreventive effect of statin therapy have yielded conflicting results. We sought to clarify whether long-term statin therapy has a chemopreventive effect on the risk of colorectal cancer (CRC) in a large, population-representative cohort. METHODS: A nested case-control study was conducted among patients \textgreater or =50 years of age and with \textgreater or =5 years of CRC-free initial follow-up in the General Practice Research Database (GPRD; 1987-2002). Cases consisted of all patients with incident CRC. Up to 10 controls were matched with each case on practice site and both duration and calendar time of follow-up prior to the index date. The primary exposure of interest was \textgreater or =5 years of cumulative statin use. RESULTS: We identified 4432 incident CRC cases and 44 292 controls. The adjusted odds ratio (OR) for \textgreater or =5 years of statin exposure was 1.1 (95% confidence interval (CI): 0.5-2.2). Chronic NSAID/aspirin use did not modify this primary association (test for interaction, p = 0.5). Compared to statin non-users, the adjusted OR for 10 years of statin exposure was 1.3 (95% CI: 0.6-2.7), and the adjusted OR associated with the highest quartile of cumulative statin dose was 1.2 (95% CI: 0.9-1.7). There was a non-statistically significant trend towards a possible reduction in CRC risk among users of high daily statin dose. CONCLUSION: Long-term statin therapy at usual doses was not associated with a significantly reduced risk of CRC. A chemopreventive effect at high daily doses cannot be excluded.
@article{yang_chronic_2008,
title = {Chronic statin therapy and the risk of colorectal cancer},
volume = {17},
issn = {1099-1557},
doi = {10.1002/pds.1599},
abstract = {BACKGROUND AND AIMS: Epidemiologic studies on a potential chemopreventive effect of statin therapy have yielded conflicting results. We sought to clarify whether long-term statin therapy has a chemopreventive effect on the risk of colorectal cancer (CRC) in a large, population-representative cohort.
METHODS: A nested case-control study was conducted among patients {\textgreater} or =50 years of age and with {\textgreater} or =5 years of CRC-free initial follow-up in the General Practice Research Database (GPRD; 1987-2002). Cases consisted of all patients with incident CRC. Up to 10 controls were matched with each case on practice site and both duration and calendar time of follow-up prior to the index date. The primary exposure of interest was {\textgreater} or =5 years of cumulative statin use.
RESULTS: We identified 4432 incident CRC cases and 44 292 controls. The adjusted odds ratio (OR) for {\textgreater} or =5 years of statin exposure was 1.1 (95\% confidence interval (CI): 0.5-2.2). Chronic NSAID/aspirin use did not modify this primary association (test for interaction, p = 0.5). Compared to statin non-users, the adjusted OR for 10 years of statin exposure was 1.3 (95\% CI: 0.6-2.7), and the adjusted OR associated with the highest quartile of cumulative statin dose was 1.2 (95\% CI: 0.9-1.7). There was a non-statistically significant trend towards a possible reduction in CRC risk among users of high daily statin dose.
CONCLUSION: Long-term statin therapy at usual doses was not associated with a significantly reduced risk of CRC. A chemopreventive effect at high daily doses cannot be excluded.},
language = {eng},
number = {9},
journal = {Pharmacoepidemiology and Drug Safety},
author = {Yang, Yu-Xiao and Hennessy, Sean and Propert, Kathleen and Hwang, Wei-Ting and Sarkar, Monika and Lewis, James D.},
month = sep,
year = {2008},
pmid = {18412290},
keywords = {Aged, Case-Control Studies, Cohort Studies, Colorectal Neoplasms, Female, Follow-Up Studies, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, Risk Factors, Time, incidence},
pages = {869--876}
}
Downloads: 0
{"_id":"T4BJtpMi5MnnPyqs3","bibbaseid":"yang-hennessy-propert-hwang-sarkar-lewis-chronicstatintherapyandtheriskofcolorectalcancer-2008","downloads":0,"creationDate":"2017-08-15T09:38:11.380Z","title":"Chronic statin therapy and the risk of colorectal cancer","author_short":["Yang, Y.","Hennessy, S.","Propert, K.","Hwang, W.","Sarkar, M.","Lewis, J. D."],"year":2008,"bibtype":"article","biburl":"http://bibbase.org/zotero/veegee78","bibdata":{"bibtype":"article","type":"article","title":"Chronic statin therapy and the risk of colorectal cancer","volume":"17","issn":"1099-1557","doi":"10.1002/pds.1599","abstract":"BACKGROUND AND AIMS: Epidemiologic studies on a potential chemopreventive effect of statin therapy have yielded conflicting results. We sought to clarify whether long-term statin therapy has a chemopreventive effect on the risk of colorectal cancer (CRC) in a large, population-representative cohort. METHODS: A nested case-control study was conducted among patients \\textgreater or =50 years of age and with \\textgreater or =5 years of CRC-free initial follow-up in the General Practice Research Database (GPRD; 1987-2002). Cases consisted of all patients with incident CRC. Up to 10 controls were matched with each case on practice site and both duration and calendar time of follow-up prior to the index date. The primary exposure of interest was \\textgreater or =5 years of cumulative statin use. RESULTS: We identified 4432 incident CRC cases and 44 292 controls. The adjusted odds ratio (OR) for \\textgreater or =5 years of statin exposure was 1.1 (95% confidence interval (CI): 0.5-2.2). Chronic NSAID/aspirin use did not modify this primary association (test for interaction, p = 0.5). Compared to statin non-users, the adjusted OR for 10 years of statin exposure was 1.3 (95% CI: 0.6-2.7), and the adjusted OR associated with the highest quartile of cumulative statin dose was 1.2 (95% CI: 0.9-1.7). There was a non-statistically significant trend towards a possible reduction in CRC risk among users of high daily statin dose. CONCLUSION: Long-term statin therapy at usual doses was not associated with a significantly reduced risk of CRC. A chemopreventive effect at high daily doses cannot be excluded.","language":"eng","number":"9","journal":"Pharmacoepidemiology and Drug Safety","author":[{"propositions":[],"lastnames":["Yang"],"firstnames":["Yu-Xiao"],"suffixes":[]},{"propositions":[],"lastnames":["Hennessy"],"firstnames":["Sean"],"suffixes":[]},{"propositions":[],"lastnames":["Propert"],"firstnames":["Kathleen"],"suffixes":[]},{"propositions":[],"lastnames":["Hwang"],"firstnames":["Wei-Ting"],"suffixes":[]},{"propositions":[],"lastnames":["Sarkar"],"firstnames":["Monika"],"suffixes":[]},{"propositions":[],"lastnames":["Lewis"],"firstnames":["James","D."],"suffixes":[]}],"month":"September","year":"2008","pmid":"18412290","keywords":"Aged, Case-Control Studies, Cohort Studies, Colorectal Neoplasms, Female, Follow-Up Studies, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, Risk Factors, Time, incidence","pages":"869--876","bibtex":"@article{yang_chronic_2008,\n\ttitle = {Chronic statin therapy and the risk of colorectal cancer},\n\tvolume = {17},\n\tissn = {1099-1557},\n\tdoi = {10.1002/pds.1599},\n\tabstract = {BACKGROUND AND AIMS: Epidemiologic studies on a potential chemopreventive effect of statin therapy have yielded conflicting results. We sought to clarify whether long-term statin therapy has a chemopreventive effect on the risk of colorectal cancer (CRC) in a large, population-representative cohort.\nMETHODS: A nested case-control study was conducted among patients {\\textgreater} or =50 years of age and with {\\textgreater} or =5 years of CRC-free initial follow-up in the General Practice Research Database (GPRD; 1987-2002). Cases consisted of all patients with incident CRC. Up to 10 controls were matched with each case on practice site and both duration and calendar time of follow-up prior to the index date. The primary exposure of interest was {\\textgreater} or =5 years of cumulative statin use.\nRESULTS: We identified 4432 incident CRC cases and 44 292 controls. The adjusted odds ratio (OR) for {\\textgreater} or =5 years of statin exposure was 1.1 (95\\% confidence interval (CI): 0.5-2.2). Chronic NSAID/aspirin use did not modify this primary association (test for interaction, p = 0.5). Compared to statin non-users, the adjusted OR for 10 years of statin exposure was 1.3 (95\\% CI: 0.6-2.7), and the adjusted OR associated with the highest quartile of cumulative statin dose was 1.2 (95\\% CI: 0.9-1.7). There was a non-statistically significant trend towards a possible reduction in CRC risk among users of high daily statin dose.\nCONCLUSION: Long-term statin therapy at usual doses was not associated with a significantly reduced risk of CRC. A chemopreventive effect at high daily doses cannot be excluded.},\n\tlanguage = {eng},\n\tnumber = {9},\n\tjournal = {Pharmacoepidemiology and Drug Safety},\n\tauthor = {Yang, Yu-Xiao and Hennessy, Sean and Propert, Kathleen and Hwang, Wei-Ting and Sarkar, Monika and Lewis, James D.},\n\tmonth = sep,\n\tyear = {2008},\n\tpmid = {18412290},\n\tkeywords = {Aged, Case-Control Studies, Cohort Studies, Colorectal Neoplasms, Female, Follow-Up Studies, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Middle Aged, Risk Factors, Time, incidence},\n\tpages = {869--876}\n}\n\n","author_short":["Yang, Y.","Hennessy, S.","Propert, K.","Hwang, W.","Sarkar, M.","Lewis, J. D."],"key":"yang_chronic_2008","id":"yang_chronic_2008","bibbaseid":"yang-hennessy-propert-hwang-sarkar-lewis-chronicstatintherapyandtheriskofcolorectalcancer-2008","role":"author","urls":{},"keyword":["Aged","Case-Control Studies","Cohort Studies","Colorectal Neoplasms","Female","Follow-Up Studies","Humans","Hydroxymethylglutaryl-CoA Reductase Inhibitors","Male","Middle Aged","Risk Factors","Time","incidence"],"downloads":0},"search_terms":["chronic","statin","therapy","risk","colorectal","cancer","yang","hennessy","propert","hwang","sarkar","lewis"],"keywords":["aged","case-control studies","cohort studies","colorectal neoplasms","female","follow-up studies","humans","hydroxymethylglutaryl-coa reductase inhibitors","male","middle aged","risk factors","time","incidence"],"authorIDs":[],"dataSources":["FmCWXwJibZiWNzpdc"]}